Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab dose-finding study in children and adolescents with polyarticular-course juvenile idiopathic arthritis
NL-OMON46846Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sarilumab in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum serum concentration observed, Area under the concentration-time curve during a dose interval and 1 more. Started Feb 2017; status: active, not recruiting.
02
Drugs
sarilumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON46846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46846.